Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Triptolide induces apoptotic cell death of human cholangiocarcinoma cells through inhibition of myeloid cell leukemia-1

Authors: Xiwei Ding, Bin Zhang, Qingshan Pei, Jianmei Pan, Shuling Huang, Yan Yang, Zhu Zhu, Ying Lv, Xiaoping Zou

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Cholangiocarcinoma (CCA), a devastating neoplasm, is highly resistant to current chemotherapies. CCA cells frequently overexpress the antiapoptotic protein myeloid cell leukemia-1(Mcl-1), which is responsible for its extraordinary ability to evade cell death. Triptolide, a bioactive ingredient extracted from Chinese medicinal plant, has been shown to inhibit cell proliferation and induce apoptosis in several cancers.

Methods

CCK-8 assay was performed to detect cell survival rate in vitro. DAPI staining and Flow cytometry were used to analyze apoptosis. Western blot was performed to determine the expression levels of caspase-3, caspase-7, caspase-9, PARP, and Mcl-1. Quantitative real-time PCR and immunofluorescence were used to detect the expression levels of Mcl-1. The nude mice xenograft model was used to evaluate the antitumor effect of triptolide in vivo.

Results

Triptolide reduced cell viability in cholangiocarcinoma cell lines in a dose- and time-dependent manner, with IC50 values of 12.6 ± 0.6 nM, 20.5 ± 4.2 nM, and 18.5 ± 0.7 nM at 48 h for HuCCT1, QBC939, and FRH0201 respectively. Triptolide induced apoptosis in CCA cell lines in part through mitochondrial pathway. Using quantitative real-time PCR, western blot and immunofluorescence, we have shown that triptolide downregulates Mcl-1 mRNA and protein levels. Furthermore, triptolide inhibited the CCA growth in vivo.

Conclusions

Triptolide has profound antitumor effect on CCA, probably by inducing apoptosis through inhibition of Mcl-1. Triptolide would be a promising therapeutic agent for CCA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, La Vecchia C: A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol. 2013, 24 (6): 1667-1674. 10.1093/annonc/mds652.CrossRefPubMed Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, La Vecchia C: A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol. 2013, 24 (6): 1667-1674. 10.1093/annonc/mds652.CrossRefPubMed
2.
go back to reference Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H: Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012, 61 (12): 1657-1669. 10.1136/gutjnl-2011-301748.CrossRefPubMed Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H: Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012, 61 (12): 1657-1669. 10.1136/gutjnl-2011-301748.CrossRefPubMed
3.
go back to reference Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, Taylor-Robinson SD, Toledano MB: Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?. J Hepatol. 2012, 56 (4): 848-854. 10.1016/j.jhep.2011.11.015.CrossRefPubMed Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, Taylor-Robinson SD, Toledano MB: Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?. J Hepatol. 2012, 56 (4): 848-854. 10.1016/j.jhep.2011.11.015.CrossRefPubMed
4.
go back to reference Pinter M, Hucke F, Zielonke N, Waldhor T, Trauner M, Peck-Radosavljevic M, Sieghart W: Incidence and mortality trends for biliary tract cancers in Austria. Liver Int. in press Pinter M, Hucke F, Zielonke N, Waldhor T, Trauner M, Peck-Radosavljevic M, Sieghart W: Incidence and mortality trends for biliary tract cancers in Austria. Liver Int. in press
5.
go back to reference von Hahn T, Ciesek S, Wegener G, Plentz RR, Weismuller TJ, Wedemeyer H, Manns MP, Greten TF, Malek NP: Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol. 2011, 46 (9): 1092-1098.CrossRefPubMed von Hahn T, Ciesek S, Wegener G, Plentz RR, Weismuller TJ, Wedemeyer H, Manns MP, Greten TF, Malek NP: Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol. 2011, 46 (9): 1092-1098.CrossRefPubMed
6.
go back to reference Rizvi S, Gores GJ: Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013, 145 (6): 1215-1229. 10.1053/j.gastro.2013.10.013.CrossRefPubMed Rizvi S, Gores GJ: Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013, 145 (6): 1215-1229. 10.1053/j.gastro.2013.10.013.CrossRefPubMed
7.
go back to reference Brinker AM, Ma J, Lipsky PE, Raskin I: Medicinal chemistry and pharmacology of genus tripterygium (celastraceae). Phytochemistry. 2007, 68 (6): 732-766. 10.1016/j.phytochem.2006.11.029.CrossRefPubMed Brinker AM, Ma J, Lipsky PE, Raskin I: Medicinal chemistry and pharmacology of genus tripterygium (celastraceae). Phytochemistry. 2007, 68 (6): 732-766. 10.1016/j.phytochem.2006.11.029.CrossRefPubMed
8.
go back to reference Liu Q: Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol. 2011, 11 (3): 377-383. 10.1016/j.intimp.2011.01.012.CrossRefPubMed Liu Q: Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol. 2011, 11 (3): 377-383. 10.1016/j.intimp.2011.01.012.CrossRefPubMed
9.
go back to reference Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF, Yang J, Underhill CB, Zhang L: Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther. 2003, 2 (1): 65-72.PubMed Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF, Yang J, Underhill CB, Zhang L: Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther. 2003, 2 (1): 65-72.PubMed
10.
go back to reference Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH, Gores GJ: Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 2004, 64 (10): 3517-3524. 10.1158/0008-5472.CAN-03-2770.CrossRefPubMed Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH, Gores GJ: Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 2004, 64 (10): 3517-3524. 10.1158/0008-5472.CAN-03-2770.CrossRefPubMed
11.
go back to reference Choi YJ, Kim TG, Kim YH, Lee SH, Kwon YK, Suh SI, Park JW, Kwon TK: Immunosuppressant PG490 (triptolide) induces apoptosis through the activation of caspase-3 and down-regulation of XIAP in U937 cells. Biochem Pharmacol. 2003, 66 (2): 273-280. 10.1016/S0006-2952(03)00282-X.CrossRefPubMed Choi YJ, Kim TG, Kim YH, Lee SH, Kwon YK, Suh SI, Park JW, Kwon TK: Immunosuppressant PG490 (triptolide) induces apoptosis through the activation of caspase-3 and down-regulation of XIAP in U937 cells. Biochem Pharmacol. 2003, 66 (2): 273-280. 10.1016/S0006-2952(03)00282-X.CrossRefPubMed
12.
go back to reference Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, Andreeff M: Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006, 108 (2): 630-637. 10.1182/blood-2005-09-3898.CrossRefPubMedPubMedCentral Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, Andreeff M: Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006, 108 (2): 630-637. 10.1182/blood-2005-09-3898.CrossRefPubMedPubMedCentral
13.
go back to reference Phillips PA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle WE, Vickers SM, Saluja AK: Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res. 2007, 67 (19): 9407-9416. 10.1158/0008-5472.CAN-07-1077.CrossRefPubMed Phillips PA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle WE, Vickers SM, Saluja AK: Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res. 2007, 67 (19): 9407-9416. 10.1158/0008-5472.CAN-07-1077.CrossRefPubMed
14.
go back to reference Martinou JC, Youle RJ: Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell. 2011, 21 (1): 92-101. 10.1016/j.devcel.2011.06.017.CrossRefPubMedPubMedCentral Martinou JC, Youle RJ: Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell. 2011, 21 (1): 92-101. 10.1016/j.devcel.2011.06.017.CrossRefPubMedPubMedCentral
15.
go back to reference Michels J, Johnson PW, Packham G: Mcl-1. Int J Biochem Cell Biol. 2005, 37 (2): 267-271. 10.1016/j.biocel.2004.04.007.CrossRefPubMed Michels J, Johnson PW, Packham G: Mcl-1. Int J Biochem Cell Biol. 2005, 37 (2): 267-271. 10.1016/j.biocel.2004.04.007.CrossRefPubMed
16.
go back to reference Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, Rahmani M, Curiel DT, Dmitriev I, Hedvat M, Wei J, Wu B, Stebbins JL, Reed JC, Pellecchia M, Sarkar D, Fisher PB: Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs. 2011, 20 (10): 1397-1411. 10.1517/13543784.2011.609167.CrossRefPubMedPubMedCentral Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, Rahmani M, Curiel DT, Dmitriev I, Hedvat M, Wei J, Wu B, Stebbins JL, Reed JC, Pellecchia M, Sarkar D, Fisher PB: Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs. 2011, 20 (10): 1397-1411. 10.1517/13543784.2011.609167.CrossRefPubMedPubMedCentral
17.
go back to reference Gores GJ, Kaufmann SH: Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev. 2012, 26 (4): 305-311. 10.1101/gad.186189.111.CrossRefPubMedPubMedCentral Gores GJ, Kaufmann SH: Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev. 2012, 26 (4): 305-311. 10.1101/gad.186189.111.CrossRefPubMedPubMedCentral
18.
go back to reference Akagi H, Higuchi H, Sumimoto H, Igarashi T, Kabashima A, Mizuguchi H, Izumiya M, Sakai G, Adachi M, Funakoshi S, Nakamura S, Hamamoto Y, Kanai T, Takaishi H, Kawakami Y, Hibi T: Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer. 2013, 16 (1): 100-110. 10.1007/s10120-012-0153-6.CrossRefPubMed Akagi H, Higuchi H, Sumimoto H, Igarashi T, Kabashima A, Mizuguchi H, Izumiya M, Sakai G, Adachi M, Funakoshi S, Nakamura S, Hamamoto Y, Kanai T, Takaishi H, Kawakami Y, Hibi T: Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer. 2013, 16 (1): 100-110. 10.1007/s10120-012-0153-6.CrossRefPubMed
19.
go back to reference Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ: Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005, 128 (7): 2054-2065. 10.1053/j.gastro.2005.03.010.CrossRefPubMed Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ: Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005, 128 (7): 2054-2065. 10.1053/j.gastro.2005.03.010.CrossRefPubMed
20.
go back to reference Okaro AC, Deery AR, Hutchins RR, Davidson BR: The expression of antiapoptotic proteins Bcl-2, Bcl-X (L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol. 2001, 54 (12): 927-932. 10.1136/jcp.54.12.927.CrossRefPubMedPubMedCentral Okaro AC, Deery AR, Hutchins RR, Davidson BR: The expression of antiapoptotic proteins Bcl-2, Bcl-X (L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol. 2001, 54 (12): 927-932. 10.1136/jcp.54.12.927.CrossRefPubMedPubMedCentral
21.
go back to reference Meng F, Yamagiwa Y, Ueno Y, Patel T: Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol. 2006, 44 (6): 1055-1065. 10.1016/j.jhep.2005.10.030.CrossRefPubMed Meng F, Yamagiwa Y, Ueno Y, Patel T: Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol. 2006, 44 (6): 1055-1065. 10.1016/j.jhep.2005.10.030.CrossRefPubMed
22.
go back to reference Banerjee S, Thayanithy V, Sangwan V, Mackenzie TN, Saluja AK, Subramanian S: Minnelide reduces tumor burden in preclinical models of osteosarcoma. Cancer Lett. 2013, 335 (2): 412-420. 10.1016/j.canlet.2013.02.050.CrossRefPubMedPubMedCentral Banerjee S, Thayanithy V, Sangwan V, Mackenzie TN, Saluja AK, Subramanian S: Minnelide reduces tumor burden in preclinical models of osteosarcoma. Cancer Lett. 2013, 335 (2): 412-420. 10.1016/j.canlet.2013.02.050.CrossRefPubMedPubMedCentral
23.
go back to reference Rousalova I, Banerjee S, Sangwan V, Evenson K, McCauley JA, Kratzke R, Vickers SM, Saluja A, D’Cunha J: Minnelide: a novel therapeutic that promotes apoptosis in non-small cell lung carcinoma in vivo. PLoS One. 2013, 8 (10): e77411-10.1371/journal.pone.0077411.CrossRefPubMedPubMedCentral Rousalova I, Banerjee S, Sangwan V, Evenson K, McCauley JA, Kratzke R, Vickers SM, Saluja A, D’Cunha J: Minnelide: a novel therapeutic that promotes apoptosis in non-small cell lung carcinoma in vivo. PLoS One. 2013, 8 (10): e77411-10.1371/journal.pone.0077411.CrossRefPubMedPubMedCentral
24.
go back to reference Chugh R, Sangwan V, Patil SP, Dudeja V, Dawra RK, Banerjee S, Schumacher RJ, Blazar BR, Georg GI, Vickers SM, Saluja AK: A preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012, 4 (156): 156ra139-CrossRefPubMedPubMedCentral Chugh R, Sangwan V, Patil SP, Dudeja V, Dawra RK, Banerjee S, Schumacher RJ, Blazar BR, Georg GI, Vickers SM, Saluja AK: A preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012, 4 (156): 156ra139-CrossRefPubMedPubMedCentral
25.
go back to reference Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC, Andreeff M: Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood. 2008, 111 (7): 3742-3750. 10.1182/blood-2007-05-091504.CrossRefPubMedPubMedCentral Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC, Andreeff M: Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood. 2008, 111 (7): 3742-3750. 10.1182/blood-2007-05-091504.CrossRefPubMedPubMedCentral
26.
go back to reference Li CJ, Chu CY, Huang LH, Wang MH, Sheu LF, Yeh JI, Hsu HY: Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo. Cancer Lett. 2012, 319 (2): 203-213. 10.1016/j.canlet.2012.01.006.CrossRefPubMed Li CJ, Chu CY, Huang LH, Wang MH, Sheu LF, Yeh JI, Hsu HY: Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo. Cancer Lett. 2012, 319 (2): 203-213. 10.1016/j.canlet.2012.01.006.CrossRefPubMed
27.
go back to reference Chang WT, Kang JJ, Lee KY, Wei K, Anderson E, Gotmare S, Ross JA, Rosen GD: Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem. 2001, 276 (3): 2221-2227.CrossRefPubMed Chang WT, Kang JJ, Lee KY, Wei K, Anderson E, Gotmare S, Ross JA, Rosen GD: Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem. 2001, 276 (3): 2221-2227.CrossRefPubMed
28.
go back to reference Lee KY, Chang W, Qiu D, Kao PN, Rosen GD: PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem. 1999, 274 (19): 13451-13455. 10.1074/jbc.274.19.13451.CrossRefPubMed Lee KY, Chang W, Qiu D, Kao PN, Rosen GD: PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem. 1999, 274 (19): 13451-13455. 10.1074/jbc.274.19.13451.CrossRefPubMed
29.
go back to reference Zhu W, Li J, Wu S, Li S, Le L, Su X, Qiu P, Hu H, Yan G: Triptolide cooperates with cisplatin to induce apoptosis in gemcitabine-resistant pancreatic cancer. Pancreas. 2012, 41 (7): 1029-1038. 10.1097/MPA.0b013e31824abdc0.CrossRefPubMed Zhu W, Li J, Wu S, Li S, Le L, Su X, Qiu P, Hu H, Yan G: Triptolide cooperates with cisplatin to induce apoptosis in gemcitabine-resistant pancreatic cancer. Pancreas. 2012, 41 (7): 1029-1038. 10.1097/MPA.0b013e31824abdc0.CrossRefPubMed
30.
go back to reference Clawson KA, Borja-Cacho D, Antonoff MB, Saluja AK, Vickers SM: Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma. J Surg Res. 2010, 163 (2): 244-249. 10.1016/j.jss.2010.03.067.CrossRefPubMedPubMedCentral Clawson KA, Borja-Cacho D, Antonoff MB, Saluja AK, Vickers SM: Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma. J Surg Res. 2010, 163 (2): 244-249. 10.1016/j.jss.2010.03.067.CrossRefPubMedPubMedCentral
31.
go back to reference Panichakul T, Intachote P, Wongkajorsilp A, Sripa B, Sirisinha S: Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis. Anticancer Res. 2006, 26 (1A): 259-265.PubMed Panichakul T, Intachote P, Wongkajorsilp A, Sripa B, Sirisinha S: Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis. Anticancer Res. 2006, 26 (1A): 259-265.PubMed
Metadata
Title
Triptolide induces apoptotic cell death of human cholangiocarcinoma cells through inhibition of myeloid cell leukemia-1
Authors
Xiwei Ding
Bin Zhang
Qingshan Pei
Jianmei Pan
Shuling Huang
Yan Yang
Zhu Zhu
Ying Lv
Xiaoping Zou
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-271

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine